<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>JNC 8 Quick Reference & Compelling Indications</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="hypertension-drug-therapy.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 100%;"></div>
                        </div>
                       <span class="progress-text">Lecture 4 of 4</span>
                    </div>
                    <a href="#" class="nav-button disabled">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">JNC 8 Quick Reference & Compelling Indications</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                <!-- START: section-jnc8-algorithm -->
                <section id="section-jnc8-algorithm" class="content-section" aria-labelledby="section-heading-1">
                    <h2 id="section-heading-1" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">JNC 8 Hypertension Guideline Algorithm</span>
                    </h2>
                    <div class="content-card">
                        <img src="../assets/images/2025_06_28_a1f43d193632bfd093c6g-1-1.jpg" alt="Flowchart of the JNC 8 Hypertension Guideline Algorithm. It shows treatment initiation based on age, and presence of diabetes or chronic kidney disease, with specific drug class recommendations for each path." class="content-image">
                    </div>
                </section>
                <!-- END: section-jnc8-algorithm -->

                <!-- START: section-compelling-indications -->
                <section id="section-compelling-indications" class="content-section" aria-labelledby="section-heading-2">
                    <h2 id="section-heading-2" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Compelling Indications</span>
                    </h2>
                    <div class="content-card">
                        <div class="table-container">
                            <table class="content-table">
                                <caption>Compelling Indications for Specific Treatment Choices</caption>
                                <thead>
                                    <tr>
                                        <th>Indication</th>
                                        <th>Treatment Choice</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>Heart Failure</td>
                                        <td>ACEI/ARB + BB + diuretic + spironolactone</td>
                                    </tr>
                                    <tr>
                                        <td>Post-MI/Clinical CAD</td>
                                        <td>ACEI/ARB AND BB</td>
                                    </tr>
                                    <tr>
                                        <td>CAD</td>
                                        <td>ACEI, BB, diuretic, CCB</td>
                                    </tr>
                                    <tr>
                                        <td>Diabetes</td>
                                        <td>ACEI/ARB, CCB, diuretic</td>
                                    </tr>
                                    <tr>
                                        <td>CKD</td>
                                        <td>ACEI/ARB</td>
                                    </tr>
                                    <tr>
                                        <td>Recurrent stroke prevention</td>
                                        <td>ACEI, diuretic</td>
                                    </tr>
                                    <tr>
                                        <td>Pregnancy</td>
                                        <td>labetolol (first line), nifedipine, methyldopa</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </section>
                <!-- END: section-compelling-indications -->

                <!-- START: section-jnc8-treatment-summary -->
                <section id="section-jnc8-treatment-summary" class="content-section" aria-labelledby="section-heading-3">
                    <h2 id="section-heading-3" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Hypertension Treatment Summary</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">Beta-1 Selective Beta-blockers</h3>
                        <p>These are possibly safer in patients with COPD, asthma, diabetes, and peripheral vascular disease:</p>
                        <ul>
                            <li>metoprolol</li>
                            <li>bisoprolol</li>
                            <li>betaxolol</li>
                            <li>acebutolol</li>
                        </ul>
                        <div class="table-container">
                            <table class="content-table">
                                <caption>Drug Class Summary</caption>
                                <thead>
                                    <tr>
                                        <th>Drug Class</th>
                                        <th>Agents of Choice</th>
                                        <th>Comments</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>Diuretics</td>
                                        <td>
                                            HCTZ 12.5-50 mg, chlorthalidone 12.5-25 mg, indapamide 1.25-2.5 mg triamterene 100 mg<br>
                                            K+ sparing - spironolactone 25-50 mg, amiloride 5-10 mg, triamterene 100 mg<br>
                                            furosemide 20-80 mg twice daily, torsemide 10-40 mg
                                        </td>
                                        <td>
                                            Monitor for hypokalemia<br>
                                            Most SE are metabolic in nature<br>
                                            Most effective when combined w/ ACEI<br>
                                            Stronger clinical evidence w/chlorthalidone<br>
                                            Spironolactone - gynecomastia and hyperkalemia<br>
                                            Loop diuretics may be needed when GFR <40 mL/min
                                        </td>
                                    </tr>
                                    <tr>
                                        <td>ACEI/ARB</td>
                                        <td>
                                            ACEI: lisinopril, benazapril, fosinopril and quinapril 10-40 mg, ramipril 5-10 mg , trandolapril 2-8 mg<br>
                                            ARB: candesartan 8-32 mg, valsartan 80-320 mg, losartan 50-100 mg, olmesartan 20-40 mg, telmisartan 20-80 mg
                                        </td>
                                        <td>
                                            SE: Cough (ACEI only), angioedema (more with ACEI), hyperkalemia<br>
                                            Losartan lowers uric acid levels; candesartan may prevent migraine headaches
                                        </td>
                                    </tr>
                                    <tr>
                                        <td>Beta-Blockers</td>
                                        <td>
                                            metoprolol succinate 50-100 mg and tartrate 50-100 mg twice daily, nebivolol 5-10 mg, propranolol 40-120 mg twice daily, carvedilol 6.25-25 mg twice daily, bisoprolol 5-10 mg, labetalol 100-300 mg twice daily,
                                        </td>
                                        <td>
                                            Not first line agents - reserve for post-MI/CHF<br>
                                            Cause fatigue and decreased heart rate<br>
                                            Adversely affect glucose; mask hypoglycemic awareness
                                        </td>
                                    </tr>
                                    <tr>
                                        <td>Calcium channel blockers</td>
                                        <td>
                                            Dihydropyridines: amlodipine 5-10 mg, nifedipine ER 30-90 mg,<br>
                                            Non-dihydropyridines: diltiazem ER 180-360 mg, verapamil 80-120 mg 3 times daily or ER 240-480 mg
                                        </td>
                                        <td>
                                            Cause edema; dihydropyridines may be safely combined w/ B-blocker<br>
                                            Non-dihydropyridines reduce heart rate and proteinuria
                                        </td>
                                    </tr>
                                    <tr>
                                        <td>Vasodilators</td>
                                        <td>
                                            hydralazine 25-100 mg twice daily, minoxidil 5-10 mg<br>
                                            terazosin 1-5 mg, doxazosin 1-4 mg given at bedtime
                                        </td>
                                        <td>
                                            Hydralazine and minoxidil may cause reflex tachycardia and fluid retention - usually require diuretic + B-blocker<br>
                                            Alpha-blockers may cause orthostatic hypotension
                                        </td>
                                    </tr>
                                    <tr>
                                        <td>Centrally-acting Agents</td>
                                        <td>
                                            clonidine 0.1-0.2 mg twice daily, methyldopa 250-500 mg twice daily<br>
                                            guanfacine 1-3 mg
                                        </td>
                                        <td>
                                            Clonidine available in weekly patch formulation for resistant hypertension
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </section>
                <!-- END: section-jnc8-treatment-summary -->

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="hypertension-drug-therapy.html" class="nav-button"> 
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 100%;"></div>
                        </div>
                       <span class="progress-text">Lecture 4 of 4</span>
                    </div>
                    <a href="#" class="nav-button disabled">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>
</html>